Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review.
Cardiovascular Agents
/ therapeutic use
Cardiovascular Diseases
/ etiology
Diabetes Mellitus, Type 2
/ complications
Glucagon-Like Peptide-1 Receptor
/ agonists
Humans
Hypoglycemic Agents
/ therapeutic use
Protective Agents
/ therapeutic use
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Cardiovascular Diseases (CVD)
Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA)
Major Adverse Cardiovascular
Events (MACE)
Type 2 Diabetes Mellitus (T2DM)
meta-analysis
Journal
Current diabetes reviews
ISSN: 1875-6417
Titre abrégé: Curr Diabetes Rev
Pays: United Arab Emirates
ID NLM: 101253260
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
02
2020
revised:
22
04
2020
accepted:
14
05
2020
pubmed:
23
5
2020
medline:
25
9
2020
entrez:
23
5
2020
Statut:
ppublish
Résumé
We thought to delve deeper into seven meta-analyses of major clinical trials focusing on Glucagon-Like Peptide-One Receptor Agonist (GLP-1 RA) cardioprotective effect. We explored the role of GLP-1 RA in cardiovascular risk protection as the primary outcome in subjects with type 2 diabetes mellitus. The current review has explored and critically appraised seven meta-analyses of placebo- controlled randomized clinical trials (RCT-s) involving GLP-1 RA used in diabetes that has exhibited major cardiovascular events as the primary outcome. Based on the participants-intervention-comparison and outcomes (PICO), the total number of the participants in this review were (138750), the intervention was conducted with GLP-1 RA, the comparator was a placebo and the outcome was major cardiovascular events. The overall evidence for the cardioprotective effect of GLP-1 RA in diabetes was very clear in subjects with the cardiovascular risk of varying degrees. Most of the currently reviewed meta-analyses have not shown cardioprotection with GLP-1 RA in subjects with diabetes exhibiting high cardiovascular risk or medical history of cardiovascular diseases. Patient variability, in addition to potency parameters, will be the key to a successful member of the class. There will be avenues for selection of a candidate based on the suitability to patient preferences and characteristics. The RCT-s for GLP-1 RA should characterize cardiovascular risk in subjects with diabetes such that disparities between established cardiovascular risk (high, moderate and low) or medical history of cardiovascular disease have been accounted for in subgroup analysis.
Sections du résumé
BACKGROUND
We thought to delve deeper into seven meta-analyses of major clinical trials focusing on Glucagon-Like Peptide-One Receptor Agonist (GLP-1 RA) cardioprotective effect.
AIM
We explored the role of GLP-1 RA in cardiovascular risk protection as the primary outcome in subjects with type 2 diabetes mellitus.
METHODOLOGY
The current review has explored and critically appraised seven meta-analyses of placebo- controlled randomized clinical trials (RCT-s) involving GLP-1 RA used in diabetes that has exhibited major cardiovascular events as the primary outcome.
RESULTS
Based on the participants-intervention-comparison and outcomes (PICO), the total number of the participants in this review were (138750), the intervention was conducted with GLP-1 RA, the comparator was a placebo and the outcome was major cardiovascular events. The overall evidence for the cardioprotective effect of GLP-1 RA in diabetes was very clear in subjects with the cardiovascular risk of varying degrees. Most of the currently reviewed meta-analyses have not shown cardioprotection with GLP-1 RA in subjects with diabetes exhibiting high cardiovascular risk or medical history of cardiovascular diseases. Patient variability, in addition to potency parameters, will be the key to a successful member of the class. There will be avenues for selection of a candidate based on the suitability to patient preferences and characteristics.
CONCLUSION
The RCT-s for GLP-1 RA should characterize cardiovascular risk in subjects with diabetes such that disparities between established cardiovascular risk (high, moderate and low) or medical history of cardiovascular disease have been accounted for in subgroup analysis.
Identifiants
pubmed: 32442089
pii: CDR-EPUB-106847
doi: 10.2174/1573399816666200522214554
doi:
Substances chimiques
Cardiovascular Agents
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Protective Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
820-832Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.